Comparative Pharmacology
Head-to-head clinical analysis: AK FLUOR 25 versus EVANS BLUE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AK FLUOR 25 versus EVANS BLUE.
AK-FLUOR 25% vs EVANS BLUE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sodium fluorescein absorbs light in the blue spectrum (465-490 nm) and emits yellow-green fluorescence (520-530 nm), enabling visualization of the retinal and choroidal vasculature by highlighting areas of vascular leakage, staining defects, or filling defects.
Evans Blue is a diazo dye that binds reversibly to plasma proteins, primarily albumin. Its primary utility is as a visual indicator for the estimation of blood volume or plasma volume via dye dilution technique. It also has histological applications for staining myelin sheaths and detecting blood-brain barrier disruption.
Intravenous administration: 5-15 mg/kg as a single bolus injection over 1-2 minutes. For ophthalmic use: 1-2 drops of 2% fluorescein solution topically.
Adults: 0.5-1.0 mL of 0.5% solution (2.5-5 mg) IV bolus for determination of blood volume. Repeat doses must be separated by at least 1 hour due to slow clearance.
None Documented
None Documented
Terminal half-life: 1-2 minutes (fluorescence decay); clinical context: transient plasma fluorescence, minimal systemic accumulation
Terminal elimination half-life ranges from 2 to 12 hours, mean approximately 6 hours; prolonged in hepatic impairment or decreased albumin levels.
Renal: >90% unchanged within 24-48 hours; <10% fecal via biliary elimination
Primarily excreted unchanged in bile (80-90%) into feces; renal elimination accounts for <5% due to high protein binding.
Category C
Category C
Diagnostic Dye
Diagnostic Dye